127 related articles for article (PubMed ID: 25491112)
1. Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-α (PPAR-α) agonists.
Gangwal RP; Damre MV; Das NR; Sharma SS; Sangamwar AT
Bioorg Med Chem Lett; 2015 Jan; 25(2):270-5. PubMed ID: 25491112
[TBL] [Abstract][Full Text] [Related]
2. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
[TBL] [Abstract][Full Text] [Related]
3. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
4. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
5. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Shibata Y; Kagechika K; Yamaguchi M; Kubo H; Usui H
Bioorg Med Chem Lett; 2012 Dec; 22(23):7075-9. PubMed ID: 23084275
[TBL] [Abstract][Full Text] [Related]
7. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
Markt P; Petersen RK; Flindt EN; Kristiansen K; Kirchmair J; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T
J Med Chem; 2008 Oct; 51(20):6303-17. PubMed ID: 18821746
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists.
Ban S; Kasuga J; Nakagome I; Nobusada H; Takayama F; Hirono S; Kawasaki H; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2011 May; 19(10):3183-91. PubMed ID: 21530275
[TBL] [Abstract][Full Text] [Related]
12. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
Kasuga J; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.
Lather V; Kairys V; Fernandes MX
Chem Biol Drug Des; 2009 Apr; 73(4):428-41. PubMed ID: 19243388
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
Yamazaki Y; Abe K; Toma T; Nishikawa M; Ozawa H; Okuda A; Araki T; Oda S; Inoue K; Shibuya K; Staels B; Fruchart JC
Bioorg Med Chem Lett; 2007 Aug; 17(16):4689-93. PubMed ID: 17553678
[TBL] [Abstract][Full Text] [Related]
16. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
[TBL] [Abstract][Full Text] [Related]
17. Exploring binding mode assessment of novel kaempferol, resveratrol, and quercetin derivatives with PPAR-α as potent drug candidates against cancer.
Ballav S; Lokhande KB; Yadav RS; Ghosh P; Swamy KV; Basu S
Mol Divers; 2023 Dec; 27(6):2867-2885. PubMed ID: 36544031
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Asaki T; Aoki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
Bioorg Med Chem; 2008 Jan; 16(2):981-94. PubMed ID: 17964792
[TBL] [Abstract][Full Text] [Related]
19. [Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands].
Miyachi H
Yakugaku Zasshi; 2004 Nov; 124(11):803-13. PubMed ID: 15516807
[TBL] [Abstract][Full Text] [Related]
20. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
